Table 3.

Impact of ASI use on OS and PFS

OSPFS
NMedian (mo)PHRa (95% CI)Median (mo)PHRa (95% CI)
Overall cohort (n = 4,736)
 ASI users1,48726.68Test8.34Test
 Other antihypertensive therapy usersb78318.070.01050.838 (0.731–0.960)6.700.02610.877 (0.782–0.984)
 Antihypertensive therapy nonusers2,46616.720.00260.810 (0.707–0.929)6.350.42260.955 (0.855–1.068)
Overall cohort by type of therapy (n = 4,736)
 VEGF therapy (n = 3511)
  ASI users1,19231.12<0.00010.737 (0.640–0.848)10.150.08690.907 (0.812–1.014)
  ASI nonusers2,31920.218.09
 mTOR Therapy (n = 665)
  ASI users15112.660.29750.867 (0.664–1.134)5.460.56500.929 (0.725–1.192)
  ASI nonusers51410.164.05
 IFNα therapy (n = 560)
  ASI users14415.540.20271.218 (0.899–1.647)3.840.90840.984 (0.747–1.297)
  ASI nonusers41614.823.68
Patients receiving VEGF-targeted and antihypertensive therapy (n = 1,769)
 ASI users1,19231.120.00030.725 (0.609–0.861)10.150.01210.835 (0.726–0.962)
 Other antihypertensive therapy usersb57721.947.82
Patients receiving VEGF-targeted therapy who developed treatment-associated hypertension (n = 2,466)
 ASI users98233.190.00040.742 (0.629–0.875)10.920.04980.883 (0.779–1.000)
 ASI nonusers1,48424.649.05

NOTE: Bolded P values are statistically significant.

Abbreviation: IMDC, International mRCC Database Consortium.

  • aHR of ASI users to comparator group from multivariate analysis, adjusted for age, sex, race, Memorial Sloan Kettering Cancer Center (MSKCC) risk factors, presence of baseline hypertension, and the development of treatment-associated hypertension.

  • bOther antihypertensive agents include β-blockers, calcium-channel blockers, diuretics, and other agents.